“Sri Lanka’s Participation at the 54th Global Fund Board Meeting”

The 54th Board Meeting of the Global Fund concluded on 13 February 2026 in Geneva, Switzerland. The South East Asia Constituency (SEA Constituency) had a strong presence at the meeting, delivering nine formal interventions and holding seven bilateral meetings with key partners and stakeholders.

Sri Lanka was represented by Dr. Anil Jasinghe, Secretary to the Ministry of Health and Mass Media and Chairman of the Country Coordinating Mechanism Sri Lanka (CCMSL). His contributions were integral to the interventions presented by the SEA Constituency, ensuring Sri Lanka’s priorities were reflected in the discussions.

Key Engagements

The SEA Constituency held bilateral meetings with:

Implementer Group Leadership

Canada / Switzerland / Australia

The United Kingdom

Western Pacific Constituency

Roll Back Malaria Partnership

Chair of the Board Leadership Nomination Committee

World Health Organization (WHO)

Major Board Decisions

Two important funding decisions were made:

US$260 million approved for Catalytic Investments, with additional contributions expected from the private sector.

US$10.8 billion confirmed for GC8 country allocations, representing a 6.6% reduction compared to GC7. Allocations will be differentiated based on economic capacity and disease burden.

The SEA Constituency consistently emphasized the importance of ensuring that allocation reductions do not undermine the significant gains achieved in the region, particularly in tuberculosis control and malaria elimination. The Global Fund Secretariat will calculate individual country allocations, which are expected to be communicated in the coming months.

Sri Lanka’s Role

CCMSL congratulates the entire SEA Constituency team for their strong representation and advocacy. We are particularly proud that our Chairman, Dr. Anil Jasinghe, represented Sri Lanka and provided valuable contributions to the interventions. His participation underscores Sri Lanka’s commitment to advancing global health priorities and safeguarding the progress made in disease control and elimination

Scroll to Top